- Asbestos
- Class Actions
- Commercial Litigation
- Defective Products
- Drug Injury
- Personal Injury
- Securities Fraud
- Toxic Exposure
- Accutane Side Effects
- Darvon and Darvocet
- DePuy Hip Recall
- Fosamax Femur Fractures
- Muscle Injury
- Sleeping Pill Dangers
- SSRI Birth Defects
- Topamax Birth Defects
- Transvaginal Surgical Mesh and Bladder Slings
- Tylenol Liver Damage
- Zocor/Simvastatin
Pending Settlements
Archives : 2011 : September
Judge Denies Defendant’s Request for New Accutane Trial
Last week, Judge Carol Higbee denied a request by Hoffman-LaRoche, the makers of Accutane, regarding the suit won by Seeger Weiss client Andy McCarrell last year. Roche’s request would have reconsidered the groundbreaking decision that awarded Andy $25.16 million. In her statement upholding the original award, Judge Higbee wrote, “[McCarrell's] testimony and that of his wife and doctors presented a picture of probably the worst case of pain, suffering and loss of quality of life I ever heard described on my eighteen years on the bench.”
Learn More about our Accutane Investigation
FDA Panels Recommend Clearer Fosamax Labels
Fosamax, the subject of an ongoing Seeger Weiss investigation, is one of the four brands of bisphosphonates discussed in two advisory panels to the FDA on September 9. Bisphosphonates, drugs prescribed to women at risk of osteoporosis, have in recent years been demonstrated to cause fractures to the femur. Examining the mounting evidence, including the testimony of 18 victims who suffered atypical femoral fractures after taking the medication, the panels voted to recommend more specific instructions for how long Fosamax and other bisphosphonates should be used.
Subscribe to our RSS